Bering Capital
Bering Capital is a venture capital investment firm based in San Francisco, California, founded in 2020. The firm specializes in investing in innovative biotech and medical technology companies, aiming to support advancements in these critical sectors. As a Registered Investment Adviser, Bering Capital focuses on identifying and nurturing cutting-edge technologies that have the potential to transform healthcare and improve patient outcomes. Through its investments, the firm seeks to drive growth and innovation within the biotech and medical technology industries.
Top Stages
4 past transactions
CalciMedica
Post in 2024
CalciMedica is a biopharmaceutical company focused on developing therapeutics for inflammatory and autoimmune disorders. It specializes in discovering and developing small molecule drugs that target calcium release-activated calcium channels.
OncoResponse
Venture Round in 2023
OncoResponse is an immuno‑oncology biotechnology company that uses a proprietary human antibody platform to discover novel targets and develop fully human monoclonal antibodies for cancer treatment. By interrogating the adaptive immune system of patients who respond exceptionally well to checkpoint inhibition, the company identifies genuine human antibodies against high‑value targets linked with immunosuppressive myeloid biology. Its pipeline aims to alleviate tumor‑microenvironment immunosuppression and enhance immune activation, converting cold tumors into hot ones and providing new therapeutic options for patients.
OncoResponse
Series C in 2021
OncoResponse is an immuno‑oncology biotechnology company that uses a proprietary human antibody platform to discover novel targets and develop fully human monoclonal antibodies for cancer treatment. By interrogating the adaptive immune system of patients who respond exceptionally well to checkpoint inhibition, the company identifies genuine human antibodies against high‑value targets linked with immunosuppressive myeloid biology. Its pipeline aims to alleviate tumor‑microenvironment immunosuppression and enhance immune activation, converting cold tumors into hot ones and providing new therapeutic options for patients.
CalciMedica
Series C in 2020
CalciMedica is a biopharmaceutical company focused on developing therapeutics for inflammatory and autoimmune disorders. It specializes in discovering and developing small molecule drugs that target calcium release-activated calcium channels.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.